Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000537094 | SCV000645235 | likely benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2022-07-11 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000992930 | SCV001145537 | uncertain significance | not provided | 2018-12-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002420466 | SCV002724261 | uncertain significance | Inborn genetic diseases | 2023-11-28 | criteria provided, single submitter | clinical testing | The c.2005A>T (p.N669Y) alteration is located in exon 10 (coding exon 8) of the SETX gene. This alteration results from a A to T substitution at nucleotide position 2005, causing the asparagine (N) at amino acid position 669 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004732940 | SCV005360061 | uncertain significance | SETX-related disorder | 2024-04-22 | no assertion criteria provided | clinical testing | The SETX c.2005A>T variant is predicted to result in the amino acid substitution p.Asn669Tyr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0054% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |